shares of Millendo Therapeutics Inc (MLND) on
Millendo Therapeutics, Inc. engages in the development of treatments for orphan endocrine diseases. The company is headquartered in Ann Arbor, Michigan and currently employs 35 full-time employees. The firm is focused on developing novel treatments for orphan endocrine diseases. The firm is focused on advancing two product candidates to treat three indications. Its advanced product candidate, livoletide (AZP-531), is a potential treatment for Prader-Willi syndrome (PWS), which is a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. The company is also developing nevanimibe (ATR-101) with a primary focus on treating patients with classic congenital adrenal hyperplasia (CAH), which is a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol.